Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Executive Summary
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
You may also be interested in...
NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.
Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
Hepalink-Backed HighTide Bets On NASH For Global Markets
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Need a specific report? 1000+ reports available
Buy Reports